I'm now testing cetuximab on HT29. In my experiment, cetuximab had no effect at all on HT29 even at a high concentration (100ug/mL ~ 0.66uM) by viability test using WST-8. This result agrees with the report such as F. Di Nicolantonio, J. Clin. Oncol. 26 (2008) 5705–5712. https://doi.org/10.1200/JCO.2008.18.0786.

However, I noticed that there are reports showing that cetuximab can inhibit HT29 proliferation such as T. Magdeldin,, J. Tissue Eng. 5 (2014). https://doi.org/10.1177/2041731414544183.

Which is correct? What is causing these opposite phenomena to be reported?

More Nobuhito Mori's questions See All
Similar questions and discussions